Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Psygen Receives Dealer’s Licence from Health Canada

Psygen Receives Dealer’s Licence from Health Canada

  • Post published:January 17, 2022
  • Post category:Press Release
Read more about the article Psygen Announces use of Psilocybin in Human Trial and Provides Update on IP Portfolio

Psygen Announces use of Psilocybin in Human Trial and Provides Update on IP Portfolio

  • Post published:October 6, 2021
  • Post category:Press Release
Read more about the article Psygen Announces Successful Closing of Oversubscribed Convertible Debenture Financing, Sets Value at $30mm

Psygen Announces Successful Closing of Oversubscribed Convertible Debenture Financing, Sets Value at $30mm

  • Post published:August 5, 2021
  • Post category:Press Release
Read more about the article Psygen Industries Ltd. and Larose Ventures Ltd. Announce Reverse Takeover Transaction of 1290442 B.C. Ltd. by Psygen Industries Ltd. and Brokered Financing Led by Eight Capital and Canaccord

Psygen Industries Ltd. and Larose Ventures Ltd. Announce Reverse Takeover Transaction of 1290442 B.C. Ltd. by Psygen Industries Ltd. and Brokered Financing Led by Eight Capital and Canaccord

  • Post published:March 24, 2021
  • Post category:Press Release
Read more about the article Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants

  • Post published:December 9, 2020
  • Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More